Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer

Ralf‐Dieter Hofheinz(University of Mannheim), G. Stehle(Boehringer Ingelheim (Germany)), P. Tanswell(Boehringer Ingelheim (Germany)), Ulrich Kunz(Boehringer Ingelheim (Germany)), D.H.J. Jager(Krankenhaus Nordwest), Hartmut Kuthan(Boehringer Ingelheim (Germany)), A. Amelsberg(Boehringer Ingelheim (Germany)), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Frank Hartmann(Universität Hamburg), C. Renner(Universitätsklinikum des Saarlandes), G. Hartung
Oncology Research and Treatment
January 1, 2003
10.1159/000069863
Cited by 364

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738